USD 9.86
(-1.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 362.03 Million USD | 21.86% |
2022 | 290.63 Million USD | 7.23% |
2021 | 271.04 Million USD | 17.93% |
2020 | 229.84 Million USD | 43.41% |
2019 | 160.27 Million USD | 108.58% |
2018 | 76.84 Million USD | 150.35% |
2017 | 30.69 Million USD | 644.1% |
2016 | 4.12 Million USD | 325.04% |
2015 | -1.83 Million USD | -249.75% |
2014 | 1.22 Million USD | 109.32% |
2013 | -13.12 Million USD | -567.8% |
2012 | -1.96 Million USD | -109.17% |
2011 | 21.43 Million USD | 2224.73% |
2010 | 922 Thousand USD | -98.57% |
2009 | 64.35 Million USD | 330.0% |
2008 | 14.96 Million USD | 738.96% |
2007 | 1.78 Million USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 113.22 Million USD | 19.59% |
2024 Q1 | 94.68 Million USD | -6.79% |
2023 Q4 | 101.57 Million USD | 8.57% |
2023 Q1 | 79.32 Million USD | 0.78% |
2023 FY | 354.15 Million USD | 21.86% |
2023 Q2 | 85.38 Million USD | 7.64% |
2023 Q3 | 93.55 Million USD | 9.56% |
2022 Q4 | 78.71 Million USD | 15.32% |
2022 FY | 290.63 Million USD | 7.23% |
2022 Q1 | 71.13 Million USD | -4.27% |
2022 Q2 | 72.53 Million USD | 1.97% |
2022 Q3 | 68.25 Million USD | -5.9% |
2021 Q2 | 69.03 Million USD | 15.32% |
2021 Q4 | 74.3 Million USD | 9.51% |
2021 FY | 271.04 Million USD | 17.93% |
2021 Q1 | 59.86 Million USD | -2.11% |
2021 Q3 | 67.84 Million USD | -1.72% |
2020 Q3 | 59.03 Million USD | 6.04% |
2020 Q1 | 53.97 Million USD | 11.63% |
2020 Q2 | 55.67 Million USD | 3.16% |
2020 FY | 229.84 Million USD | 43.41% |
2020 Q4 | 61.15 Million USD | 3.58% |
2019 Q2 | 38.76 Million USD | 29.25% |
2019 Q4 | 48.34 Million USD | 11.99% |
2019 Q3 | 43.17 Million USD | 11.37% |
2019 Q1 | 29.99 Million USD | 5.98% |
2019 FY | 160.27 Million USD | 108.58% |
2018 Q2 | 18.17 Million USD | 29.07% |
2018 Q4 | 28.3 Million USD | 73.77% |
2018 FY | 76.84 Million USD | 150.35% |
2018 Q1 | 14.08 Million USD | 16.19% |
2018 Q3 | 16.28 Million USD | -10.39% |
2017 Q1 | 3.39 Million USD | 44.92% |
2017 FY | 30.69 Million USD | 644.1% |
2017 Q4 | 12.11 Million USD | 33.41% |
2017 Q3 | 9.08 Million USD | 48.99% |
2017 Q2 | 6.09 Million USD | 79.64% |
2016 Q2 | - USD | 0.0% |
2016 FY | 4.12 Million USD | 325.04% |
2016 Q4 | 2.34 Million USD | 31.35% |
2016 Q3 | 1.78 Million USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2015 FY | -1.83 Million USD | -249.75% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 100.0% |
2015 Q2 | -8.74 Million USD | -5.21% |
2015 Q1 | -8.3 Million USD | 11.54% |
2014 Q2 | -3.7 Million USD | -1.37% |
2014 Q3 | -5.62 Million USD | -51.7% |
2014 Q1 | -3.65 Million USD | -44.33% |
2014 FY | 1.22 Million USD | 109.32% |
2014 Q4 | -9.39 Million USD | -67.04% |
2013 Q2 | -2.93 Million USD | 28.93% |
2013 Q4 | -2.53 Million USD | 30.12% |
2013 Q1 | -4.13 Million USD | -6.93% |
2013 Q3 | -3.62 Million USD | -23.38% |
2013 FY | -13.12 Million USD | -567.8% |
2012 Q2 | 10.63 Million USD | 36.83% |
2012 Q4 | -3.86 Million USD | -282.53% |
2012 Q3 | 2.11 Million USD | -80.09% |
2012 Q1 | 7.77 Million USD | 38.08% |
2012 FY | -1.96 Million USD | -109.17% |
2011 Q4 | 5.63 Million USD | -2.9% |
2011 Q3 | 5.79 Million USD | 43.51% |
2011 Q1 | 5.96 Million USD | 547.07% |
2011 Q2 | 4.04 Million USD | -32.28% |
2011 FY | 21.43 Million USD | 2224.73% |
2010 Q4 | 922 Thousand USD | 0.0% |
2010 FY | 922 Thousand USD | -98.57% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q1 | - USD | -100.0% |
2009 FY | 64.35 Million USD | 330.0% |
2009 Q4 | 49.47 Million USD | 907.04% |
2009 Q3 | 4.91 Million USD | -8.36% |
2009 Q2 | 5.36 Million USD | 16.39% |
2009 Q1 | 4.6 Million USD | 6.01% |
2008 Q1 | 3.16 Million USD | 77.13% |
2008 FY | 14.96 Million USD | 738.96% |
2008 Q3 | 3.65 Million USD | -4.05% |
2008 Q2 | 3.8 Million USD | 20.47% |
2008 Q4 | 4.34 Million USD | 18.94% |
2007 Q3 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q4 | 1.78 Million USD | 0.0% |
2007 FY | 1.78 Million USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2003 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Editas Medicine, Inc. | -99.52 Million USD | 463.747% |
Dynavax Technologies Corporation | 182.11 Million USD | -98.79% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 30.876% |
Perrigo Company plc | 1.68 Billion USD | 78.456% |
Illumina, Inc. | 2.74 Billion USD | 86.806% |
Thermo Fisher Scientific Inc. | 15.22 Billion USD | 97.622% |
Iovance Biotherapeutics, Inc. | -9.56 Million USD | 3884.549% |
Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.635% |
IQVIA Holdings Inc. | 5.23 Billion USD | 93.09% |
Heron Therapeutics, Inc. | 10.04 Million USD | -3505.158% |
Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 96.797% |
Unity Biotechnology, Inc. | -19.69 Million USD | 1937.809% |
Waters Corporation | 1.76 Billion USD | 79.444% |
Biogen Inc. | 7.3 Billion USD | 95.042% |
Sangamo Therapeutics, Inc. | -45.32 Million USD | 898.742% |
Evolus, Inc. | 140.52 Million USD | -157.625% |
Adicet Bio, Inc. | -6.09 Million USD | 6036.865% |
Cara Therapeutics, Inc. | 14.79 Million USD | -2347.141% |
bluebird bio, Inc. | -4.03 Million USD | 9083.375% |
Esperion Therapeutics, Inc. | 73.06 Million USD | -395.477% |
FibroGen, Inc. | 128.9 Million USD | -180.852% |
Agilent Technologies, Inc. | 3.46 Billion USD | 89.552% |
Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1261.557% |
Homology Medicines, Inc. | -7.22 Million USD | 5108.023% |
Geron Corporation | -123.5 Million USD | 393.135% |
Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 76.149% |
Myriad Genetics, Inc. | 476.4 Million USD | 24.007% |
Viking Therapeutics, Inc. | -292 Thousand USD | 124082.877% |
Intellia Therapeutics, Inc. | -398.79 Million USD | 190.781% |
Zoetis Inc. | 5.83 Billion USD | 93.794% |
Abeona Therapeutics Inc. | 302 Thousand USD | -119777.483% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 83.309% |
BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 80.99% |
Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 95.794% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 119581.848% |
Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 53.497% |
Atara Biotherapeutics, Inc. | -313 Thousand USD | 115764.537% |
Verastem, Inc. | -62 Thousand USD | 584019.355% |
Nektar Therapeutics | 53.47 Million USD | -576.97% |
Axsome Therapeutics, Inc. | 244.53 Million USD | -48.048% |
Aclaris Therapeutics, Inc. | -85.21 Million USD | 524.838% |
Sarepta Therapeutics, Inc. | 1.09 Billion USD | 66.877% |
OPKO Health, Inc. | 318.12 Million USD | -13.8% |
Exelixis, Inc. | 1.75 Billion USD | 79.403% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 80.403% |
Corcept Therapeutics Incorporated | 475.89 Million USD | 23.926% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 2.21 Million USD | -16244.47% |
Imunon, Inc. | -720 Thousand USD | 50381.595% |
Blueprint Medicines Corporation | 236.58 Million USD | -53.024% |
Insmed Incorporated | 239.63 Million USD | -51.076% |
Halozyme Therapeutics, Inc. | 636.89 Million USD | 43.157% |
Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1990.363% |
TG Therapeutics, Inc. | 219.1 Million USD | -65.229% |
Incyte Corporation | 3.44 Billion USD | 89.478% |
Emergent BioSolutions Inc. | 343.9 Million USD | -5.272% |